Finerenone Clinical Trials
10 recruitingDrug
Phase 35Phase 42Not Applicable1Phase 21
Showing 1–10 of 10 trials
Recruiting
Phase 3
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Chronic Kidney Diseases
The George Institute1,000 enrolled43 locationsNCT06058585
Recruiting
Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Heart FailureAcute Heart Failure
Colorado Prevention Center5,200 enrolled80 locationsNCT06008197
Recruiting
Phase 4
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
Chronic Kidney Disease(CKD)
Peter Rossing125 enrolled4 locationsNCT07239570
Recruiting
Not Applicable
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
IgA Nephropathy (IgAN)
Botkin Hospital30 enrolled1 locationNCT07056595
Recruiting
Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease
Chronic Kidney DiseaseType 2 Diabetes MellitusRenal Function
Second Affiliated Hospital of Soochow University300 enrolled1 locationNCT06838416
Recruiting
Phase 2
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
Glomerulonephritis
Alexandria University100 enrolled1 locationNCT06835322
Recruiting
Phase 3
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
Heart Failure
Colorado Prevention Center1,500 enrolled15 locationsNCT06024746
Recruiting
Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
Heart Failure
Colorado Prevention Center2,600 enrolled8 locationsNCT06033950
Recruiting
Phase 4
Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
Patients With Type 2 Diabetes
Chinese University of Hong Kong82 enrolled1 locationNCT06727409
Recruiting
Phase 3
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Heart FailureCardiovascular DiseasesType 1 Diabetes+1 more
Steno Diabetes Center Copenhagen2,000 enrolled2 locationsNCT06082063